Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

REGN7508 til voksne deltagere til forebyggelse af kræftrelateret trombose (ROXI-CAT-I)

3. november 2026 opdateret af: Regeneron Pharmaceuticals

En fase 3, multicenter, randomiseret, dobbeltblind, placebokontrolleret undersøgelse for at vurdere effektiviteten og sikkerheden af REGN7508, en monoklonal antistof mod FXI, til primær profylakse af kræftrelateret trombose hos deltagere med solide tumorer under kræftbehandling (ROXI-CAT-I)

This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants.

The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tumors who are currently receiving anticancer treatment or planning to start anticancer treatment within a month of being assigned to a study treatment, or recovering from surgery, and how the study drug compares to placebo for CAT.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Studieoversigt

Status

Rekruttering

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

1120

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Florida
      • Hialeah, Florida, Forenede Stater, 33013
        • Rekruttering
        • Bioresearch Partner- Hialeah Hospital
      • North Miami Beach, Florida, Forenede Stater, 33169
        • Rekruttering
        • Helios Clinical Research
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02215
        • Rekruttering
        • Beth Israel Deaconess Medical Center
    • New York
      • New York, New York, Forenede Stater, 10021
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center
    • Texas
      • El Paso, Texas, Forenede Stater, 79902
        • Trukket tilbage
        • El Paso Medical Research Institute (Medresearch Inc)
      • Tbilisi, Georgien, 0159
        • Rekruttering
        • Institute of Clinical Oncology
      • Tbilisi, Georgien, 0186
        • Rekruttering
        • Caucasus Medical Centre
      • Tbilisi, Georgien, 0144
        • Rekruttering
        • Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic
      • Tbilisi, Georgien, 0179
        • Rekruttering
        • LTD Cancer Research Centre
      • Tbilisi, Georgien, 0179
        • Rekruttering
        • JSC Evex Hospitals - Caraps Medline
      • Tbilisi, Georgien, 0102
        • Rekruttering
        • American Hospital Tbilisi
      • Tbilisi, Georgien, 0112
        • Rekruttering
        • Llc Todua Clinic
      • Tbilisi, Georgien, 0112
        • Rekruttering
        • Israel Georgia Medical Research Clinic Helsicore
    • Adjara
      • Batumi, Adjara, Georgien, 6000
        • Rekruttering
        • LTD High Technology Hospital Medcenter
    • Imereti
      • Kutaisi, Imereti, Georgien, 4600
        • Rekruttering
        • Krystyna Kiel Oncology Center
      • Niigata, Japan, 951-8520
        • Rekruttering
        • Niigata University Medical & Dental Hospital
    • Ehime
      • Tōon, Ehime, Japan, 791-0295
        • Rekruttering
        • Ehime University Hospital
    • Gunma
      • Ōta, Gunma, Japan, 373-8550
        • Rekruttering
        • Gunma Prefectural Cancer Center
    • Hyōgo
      • Akashi, Hyōgo, Japan, 673-8558
        • Rekruttering
        • Hyogo Cancer Center
    • Kagawa-ken
      • Kita-gun, Kagawa-ken, Japan, 761-0793
        • Rekruttering
        • Kagawa University Hospital
    • Kanagawa
      • Isehara-Shi, Kanagawa, Japan, 259-1193
        • Rekruttering
        • Tokai University Hospital
    • Kyoto
      • Kyoto, Kyoto, Japan, 602-8566
        • Rekruttering
        • University Hospital Kyoto Prefectural University of Medicine
    • Miyagi
      • Sendai, Miyagi, Japan, 980-8574
        • Rekruttering
        • Tohoku University Hospital
    • Osaka
      • Chuo, Osaka, Japan, 540-0006
        • Rekruttering
        • National Hospital Organization Osaka National Hospital (ONH)
    • Saitama
      • Ina-machi, Saitama, Japan, 362-0806
        • Rekruttering
        • Saitama Cancer Center
    • Tokyo
      • Chuo Ku, Tokyo, Japan, 104-0045
        • Rekruttering
        • National Cancer Center Hospital - Tsukiji Campus
      • Shinjuku, Tokyo, Japan, 160-0023
        • Rekruttering
        • Tokyo Medical University Hospital
    • Yamaguchi
      • Ube, Yamaguchi, Japan, 755-8505
        • Rekruttering
        • Yamaguchi University Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Key Inclusion Criteria:

  1. Has a histologically confirmed diagnosis of malignant solid tumors which are locally advanced or metastatic as described in the protocol
  2. Has a Khorana thromboembolic risk score ≥2 during screening period or harbors a somatic documented tumor genetic variant known to be associated with a similar increased risk of VTE as described in the protocol
  3. Has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2 at the time of screening and day 1 prior to the first dose of study intervention

Key Exclusion Criteria:

  1. Has known bleeding conditions (eg, Hemophilia A or B, von Willebrand's disease), hemorrhagic tumor sites, or other conditions with a high risk for bleeding (eg, hepatic disease associated with coagulopathy)
  2. Has a cancer diagnosis consisting solely of basal cell or squamous cell skin carcinoma
  3. Has a primary brain tumor or brain metastases as described in the protocol
  4. Has proximal lower extremity DVT locally detected by Compression Ultrasound (CUS) during screening period
  5. Has any condition that, as judged by the investigator, may confound the results of the study or would place the participant at increased risk of harm if he/she participated in the study

Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: Placebo

Administered per the protocol

Eksperimentel: REGN7508

Administered per the protocol

Andre navne:
  • cenvacibart

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Tid til første hændelse af centralt bedømt International Society of Thrombosis and Hemostasis (ISTH) større blødning eller klinisk relevant ikke-større (CRNM) blødning
Tidsramme: I 6 måneder
I 6 måneder
Time-to-first event of centrally adjudicated VTE (DVT, PE) or ATE, or thromboembolism- or ATE-related death
Tidsramme: Through 6 months
Through 6 months

Sekundære resultatmål

Resultatmål
Tidsramme
Forekomst af behandlingsrelaterede bivirkninger (TEAEs)
Tidsramme: Op til dag 245
Op til dag 245
Sværhedsgrad af TEAE'er
Tidsramme: Op til dag 245
Op til dag 245
Størrelsen af ADA til REGN7508
Tidsramme: Op til dag 245
Op til dag 245
Time-to-first event of the centrally adjudicated symptomatic or incidental VTE (DVT, PE) or ATE and thromboembolism- or ATE-related death
Tidsramme: Through 6 months
Through 6 months
Time-to-first event of symptomatic VTE
Tidsramme: Through 6 months
Through 6 months
Time-to-first event of symptomatic DVT
Tidsramme: Through 6 months
Through 6 months
Time-to-first event of symptomatic non-fatal PE
Tidsramme: Through 6 months
Through 6 months
Time-to-first event of thromboembolism-related death
Tidsramme: Through 6 months
Through 6 months
Time-to-first event of incidental VTE
Tidsramme: Through 6 months
Through 6 months
Time-to-first event of incidental upper extremity or incidental proximal lower extremity DVT
Tidsramme: Through 6 months
Through 6 months
Time-to-first event of incidental non-fatal PE (in a segmental or larger pulmonary artery)
Tidsramme: Through 6 months
Through 6 months
Time-to-first event of asymptomatic VTE (Asymptomatic DVT detected by lower extremities ultrasound)
Tidsramme: Through 6 months
Through 6 months
Time-to-first event of ATE
Tidsramme: Through 6 months
Through 6 months
Time-to-first event of ATE-related death
Tidsramme: Through 6 months
Through 6 months
Time-to-first event of centrally adjudicated VTE (DVT, PE), or thromboembolism-related death
Tidsramme: Through 6 months
Through 6 months
Occurrence of Anti-Drug Antibody (ADA) to REGN7508
Tidsramme: Up to day 245
Up to day 245

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: Clinical Trial Management, Regeneron Pharmaceuticals

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

9. marts 2026

Primær færdiggørelse (Anslået)

23. januar 2030

Studieafslutning (Anslået)

6. maj 2030

Datoer for studieregistrering

Først indsendt

6. februar 2026

Først indsendt, der opfyldte QC-kriterier

12. februar 2026

Først opslået (Faktiske)

13. februar 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

IPD-delingstidsramme

When Regeneron has:

  • received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
  • made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
  • the legal authority to share the data, and
  • ensured the ability to protect participant privacy

IPD-delingsadgangskriterier

Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner